🔴 SAB Biotherapeutics is trading 5% down today; no clear company-specific catalyst reported

SAB Biotherapeutics is trading at $2.54, down 5.04%, with no clear company-specific catalyst reported.

• October 13: FDA granted Fast Track designation for SAB-142; this earlier news does not establish the cause.
• October 14: The company announced healthcare conference participation, not a new clinical or regulatory milestone.
• Broader markets and biotech shares are lower after September inflation exceeded expectations, raising rate concerns and pressuring growth stocks; neither confirms what drove the move.